Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart

Circulation Research

Volumn 96, Issue 9, 2005, Pages 1006-1013

  Hu, Ying ^a   Belke, Darrell ^a   Suarez, Jorge ^a   Swanson, Eric ^a   Clark, Raymond ^a   Hoshijima, Masahiko ^a   Dillmann, Wolfgang H ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Adenovirus; Ca2+ handling; Diabetic cardiomyopathy; Gene therapy; O GlcNAcase

Indexed keywords

ADENOVIRUS VECTOR; CELL PROTEIN; N ACETYL BETA GLUCOSAMINIDASE; PHOSPHOLAMBAN; PROTEIN SARCOPLASMIC RETICULUM CALCIUM REGULATING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DIABETES MELLITUS; GENE OVEREXPRESSION; HEART LEFT VENTRICLE DP-DT; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SARCOPLASMIC RETICULUM; STREPTOZOCIN DIABETES;

ACETYLGLUCOSAMINIDASE; ACETYLTRANSFERASES; ADENOVIRIDAE; ANIMALS; BETA-N-ACETYLHEXOSAMINIDASE; CALCIUM; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; GENETIC VECTORS; HISTONE ACETYLTRANSFERASES; MICE; MULTIENZYME COMPLEXES; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; SARCOPLASMIC RETICULUM;

EID: 19044377730     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000165478.06813.58     Document Type: Article

References (54)

1. Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol. 1991;68:85-89.
2. Fein FS, Kornstein LB, Strobeck JE, Capasso JM, Sonnenblick EH. Altered myocardial mechanics in diabetic rats. Circ Res. 1980;47:922-933.
3. Zarich SW, Arbuckle BE, Cohen LR, Roberts M, Nesto RW. Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J Am Coll Cardiol. 1988;12:114-120.
4. 2+-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes. 2002;51:1166-1171.
5. Ren J, Davidoff AJ. Diabetes rapidly induces contractile dysfunctions in isolated ventricular myocytes. Am J Physiol. 1997;272:H148-H158.
6. 2+ handling in ventricular myocytes isolated from diabetic rats. Am J Physiol. 1996;270:H1529-H1537.
7. Suarez J, Belke DD, Gloss B, Dieterle T, McDonough PM, Kim YK, Brunton LL, Dillmann WH. In vivo adenoviral transfer of sorcin reverses cardiac contractile abnormalities of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2004;286:H68-H75.
8. Wells L, Hart GW. O-GlcNAc turns twenty: functional implications for post-translational modification of nuclear and cytosolic proteins with a sugar. FEBS Lett. 2003;546:154-158.
9. Wells L, Whalen SA, Hart GW. O-GlcNAc: a regulatory post-translational modification. Biochem Biophys Res Commun. 2003;302:435-441.
10. Vosseller K, Sakabe K, Wells L, Hart GW. Diverse regulation of protein function by O-GlcNAc: a nuclear and cytoplasmic carbohydrate post-translational modification. Curr Opin Chem Biol. 2002;6:851-857.
11. Comer FI, Hart GW. O-GlcNAc and the control of gene expression. Biochim Biophys Acta. 1999;1473:161-171.
12. Kneass ZT, Marchase RB. Protein O-GlcNAc modulates motiligy-associated signaling intermediates in neutrophils. J Biol Chem. 2005; 280(15):14579-14585.
13. Wells L, Gao Y, Mahoney JA, Vosseller K, Chen C, Rosen A, Hart GW. Dynamic O-glycosylation of nuclear and cytosolic proteins: further characterization of the nucleocytoplasmic β-N-acetylglucosaminidase. O-GlcNAcase. J Biol Chem. 2002;277:1755-1761.
14. Yki-Jarvinen H, Virkamaki A, Daniels MC, McClain D, Gottschalk WK. Insulin and glucosamine infusions increase O-linked N-acetyl-glucosamine in skeletal muscle proteins in vivo. Metabolism. 1998;47:449-455.
15. Marshall S, Nadeau O, Yamasaki K. Dynamic actions of glucose and glucosamine on hexosamine biosynthesis in isolated adipocytes: differential effects on glucosamine 6-phosphate, UDP-N-acetylglucosamine, and ATP levels. J Biol Chem. 2004;279:35313-35319.
16. Liu K, Paterson AJ, Chin E, Kudlow JE. Glucose stimulates protein modification by O-linked GlcNAc in pancreatic β cells: linkage of O-linked GlcNAc to beta cell death. Proc Natl Acad Sci USA. 2000;97:2820-2825.
17. Akimoto Y, Kawakami H, Yamamoto K, Munetomo E, Hida T, Hirano H. Elevated expression of O-GlcNAc-modified proteins and O-GlcNAc transferase in corneas of diabetic Goto-Kakizaki rats. Invest Ophthalmol Vis Sci. 2003;44:3802-3809.
18. Federici M, Menghini R, Mauriello A, Hribal ML, Ferrelli F, Lauro D, Sbraccia P, Spagnoli LG, Sesti G, Lauro R. Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation. 2002;106:466-472.
19. Vosseller K, Wells L, Lane MD, Hart GW. Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci USA. 2002;99:5313-5318.
20. Ren J, Gintant GA, Miller RE, Davidoff AJ. High extracellular glucose impairs cardiac E-C coupling in a glycosylation-dependent manner. Am J Physiol. 1997;273:H2876-H2883.
21. Pang Y, Bounelis P, Chatham JC, Marchase RB. Hexosamine pathway is responsible for inhibition by diabetes of phenylephrine-induced inotropy. Diabetes. 2004;53:1074-1081.
22. Clark RJ, McDonough PM, Swanson E, Trost SU, Suzuki M, Fukuda M, Dillmann WH. Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J Biol Chem. 2003;278:44230-44237.
23. Reifsnyder PC, Leiter EH. Deconstructing and reconstructing obesity-induced diabetes (diabesity) in mice. Diabetes. 2002;51:825-832.
24. Leiter EH, Reifsnyder PC. Differential levels of diabetogenic stress in two new mouse models of obesity and type 2 diabetes. Diabetes. 2004;53 Suppl 1:S4-S11.
25. 2+ transients. Circulation. 1997;96:400-403.
26. Shannon TR, Ginsburg KS, Bers DM. Quantitative assessment of the SR Ca2+ leak-load relationship. Circ Res. 2002;91:594-600.
27. He H, Meyer M, Martin JL, McDonough PM, Ho P, Lou X, Lew WY, Hilal-Dandan R, Dillmann WH. Effects of mutant and antisense RNA of phospholamban on SR Ca(2+)-ATPase activity and cardiac myocyte contractility. Circulation. 1999;100:974-980.
28. Trost SU, Omens JH, Karlon WJ, Meyer M, Mestril R, Covell JW, Dillmann WH. Protection against myocardial dysfunction after a brief ischemic period in transgenic mice expressing inducible heat shock protein 70. J Clin Invest. 1998;101:855-862.
29. Gloss B, Trost S, Bluhm W, Swanson E, Clark R, Winkfein R, Janzen K, Giles W, Chassande O, Samarut J, Dillmann W. Cardiac ion channel expression and contractile function in mice with deletion of thyroid hormone receptor alpha or beta. Endocrinology. 2001;142:544-550.
30. Haltiwanger RS, Blomberg MA, Hart GW. Glycosylation of nuclear and cytoplasmic proteins. Purification and characterization of a uridine diphospho-N-acetylglucosamine:polypeptide beta-N-acetylglucosaminyl-transferase. J Biol Chem. 1992;267:9005-9013.
31. Akimoto Y, Kreppel LK, Hirano H, Hart GW. Increased O-GlcNAc transferase in pancreas of rats with streptozotocin-induced diabetes. Diabetologia. 2000;43:1239-1247.
32. Dong DL, Xu ZS, Hart GW, Cleveland DW. Cytoplasmic O-GlcNAc modification of the head domain and the KSP repeat motif of the neurofilament protein neurofilament-H. J Biol Chem. 1996;271:20845-20852.
33. Kreppel LK, Blomberg MA, Hart GW. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J Biol Chem. 1997;272:9308-9315.
34. Kreppel LK, Hart GW. Regulation of a cytosolic and nuclear O-GlcNAc transferase. Role of the tetratricopeptide repeats. J Biol Chem. 1999;274:32015-32022.
35. Dong DL, Hart GW. Purification and characterization of an O-GlcNAc selective N-acetyl-beta-D-glucosaminidase from rat spleen cytosol. J Biol Chem. 1994;269:19321-19330.
36. Gao Y, Wells L, Comer FI, Parker GJ, Hart GW. Dynamic O-glycosylation of nuclear and cytosolic proteins: cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain. J Biol Chem. 2001;276:9838-9845.
37. Fein FS, Miller-Green B, Zola B, Sonnenblick EH. Reversibility of diabetic cardiomyopathy with insulin in rabbits. Am J Physiol. 1986;250:H108-H113.
38. Fein FS, Strobeck JE, Malhotra A, Scheuer J, Sonnenblick EH. Reversibility of diabetic cardiomyopathy with insulin in rats. Circ Res. 1981;49:1251-1261.
39. 2+-ATPase. Diabetes. 2004;53:463-473.
40. Comer FI, Hart GW. Reciprocity between O-GlcNAc and O-phosphate on the carboxyl terminal domain of RNA polymerase II. Biochemistry. 2001;40:7845-7852.
41. Roos MD, Su K, Baker JR, Kudlow JE. O glycosylation of an Sp1-derived peptide blocks known Sp1 protein interactions. Mol Cell Biol. 1997;17:6472-6480.
42. Yang X, Su K, Roos MD, Chang Q, Paterson AJ, Kudlow JE. O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. Proc Natl Acad Sci USA. 2001;98:6611-6616.
43. Yang X, Zhang F, Kudlow JE. Recruitment of O-GlcNAc transferase to promoters by corepressor mSin3A: coupling protein O-GlcNAcylation to transcriptional repression. Cell. 2002;110:69-80.
44. James LR, Tang D, Ingram A, Ly H, Thai K, Cai L, Scholey JW. Flux through the hexosamine pathway is a determinant of nuclear factor-κB-dependent promoter activation. Diabetes. 2002;51:1146-1156.
45. Fiordaliso F, Leri A, Cesselli D, Limana F, Safai B, Nadal-Ginard B, Anversa P, Kajstura J. Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes. 2001;50:2363-2375.
46. Zhang F, Su K, Yang X, Bowe DB, Paterson AJ, Kudlow JE. O-GlcNAc modification is an endogenous inhibitor of the proteasome. Cell. 2003;115:715-725.
47. Liu K, Paterson AJ, Zhang F, McAndrew J, Fukuchi K, Wyss JM, Peng L, Hu Y, Kudlow JE. Accumulation of protein O-GlcNAc modification inhibits proteasomes in the brain and coincides with neuronal apoptosis in brain areas with high O-GlcNAc metabolism. J Neurochem. 2004;89:1044-1055.
48. Han I, Kudlow JE. Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. Mol Cell Biol. 1997;17:2550-2558.
49. Reddy LG, Jones LR, Thomas DD. Depolymerization of phospholamban in the presence of calcium pump: a fluorescence energy transfer study. Biochemistry. 1999;38:3954-3962.
50. Li M, Reddy LG, Bennett R, Silva ND Jr, Jones LR, Thomas DD. A fluorescence energy transfer method for analyzing protein oligomeric structure: application to phospholamban. Biophys J. 1999;76:2587-2599.
51. Cornea RL, Jones LR, Autry JM, Thomas DD. Mutation and phosphorylation change the oligomeric structure of phospholamban in lipid bilayers. Biochemistry. 1997;36:2960-2967.
52. Frank K, Kranias EG. Phospholamban and cardiac contractility. Ann Med. 2000;32:572-578.
53. Colyer J. Phosphorylation states of phospholamban. Ann NY Acad Sci. 1998;853:79-91.
54. Lefebvre T, Ferreira S, Dupont-WaDois L, Bussiere T, Dupire MJ, Delacourte A, Michalski JC, Caillet-Boudin ML. Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins: a role in nuclear localization. Biochim Biophys Acta. 2003;1619:167-176.